BACKGROUND: Advanced @entity2460 (SFTs) are rare soft-tissue @entity242 with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of @entity4350 in a retrospective, multi-center French series of @entity1 with SFTs. METHODS: @entity1 were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. @entity4350 was administered at an initial dose of 1.5  mg/m(2), q3 weeks. The @entity5 response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with @entity4350 (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). RESULTS: Eleven @entity1 treated with @entity4350 for advanced SFT were identified. @entity4350 had been used as second-line treatment in 8 @entity1 (72.7  %) and as at least third-line therapy in a further 3 (27.3  %). The best RECIST response was a partial response (PR) in one @entity1 (9.1  %) and @entity66 ( @entity66 ) in eight @entity1 (72.7  %). Disease-control rate (DCR   =   PR   +   @entity66 ) was 81.8  %. After a median follow-up of 29.2  months, the median PFS was 11.6  months (95 % CI   =   2.0; 15.2  months) and the median OS was 22.3  months (95 % CI   =   9.1  months; not reached). The median GMI was 1.49 (range: 0.11-4.12). CONCLUSION: @entity4350 is a very promising treatment for advanced SFTs. Further investigations are needed.

Efficacy of @entity4350 in XXXX : a retrospective analysis from the @entity242 Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity4350 :: ('MESH:C099150', 'Chemical') :: ['trabectedin', 'Trabectedin'] @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['best tumor'] @entity2460 :: ('MESH:D054364', 'Disease') :: ['malignant solitary fibrous tumors']
@entity2460 :: (MESH:D054364,Disease) :: ['malignant solitary fibrous tumors']
